Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare CVE:ABCNNYSE:EMCNASDAQ:ONCTSE:PLI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABCNVIVO CannabisC$1.32+5.6%C$1.32C$0.80▼C$4.06C$256.62MN/A1.51 million shs310,601 shsEMCEMC$29.28-0.1%$0.00$22.99▼$29.13N/AN/A13.90 million shs4,651 shsONCBeOne Medicines$245.49+0.5%$247.70$142.00▼$287.88$26.91B0.28360,050 shs172,489 shsPLIProMetic Life SciencesC$0.00C$7.13▼C$590.00C$317.06MN/A8,002 shs921 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABCNVIVO Cannabis0.00%0.00%0.00%0.00%0.00%EMCEMC-0.06%+0.02%+5.24%+20.24%+6.61%ONCBeOne Medicines0.00%+1.78%-4.95%+2.93%+24,548,999,900.00%PLIProMetic Life Sciences0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABCNVIVO CannabisN/AN/AN/AN/AN/AN/AN/AN/AEMCEMCN/AN/AN/AN/AN/AN/AN/AN/AONCBeOne Medicines3.424 of 5 stars4.50.00.00.02.61.70.6PLIProMetic Life SciencesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABCNVIVO Cannabis 0.00N/AN/AN/AEMCEMC 0.00N/AN/AN/AONCBeOne Medicines 3.00Buy$320.6730.62% UpsidePLIProMetic Life Sciences 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ONC, PLI, ABCN, and EMC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/27/2025ONCBeOne MedicinesMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$313.00 ➝ $330.006/27/2025ONCBeOne MedicinesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$317.00 ➝ $321.006/27/2025ONCBeOne MedicinesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$311.005/8/2025ONCBeOne MedicinesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$312.00 ➝ $311.005/8/2025ONCBeOne MedicinesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$348.00 ➝ $350.004/28/2025ONCBeOne MedicinesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$312.00 ➝ $312.004/24/2025ONCBeOne MedicinesTD SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$334.00 ➝ $334.004/21/2025ONCBeOne MedicinesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$311.00 ➝ $317.004/16/2025ONCBeOne MedicinesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/10/2025ONCBeOne MedicinesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$348.00 ➝ $348.00(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABCNVIVO CannabisN/AN/AN/AN/AN/AN/AEMCEMCN/AN/AN/AN/AN/AN/AONCBeOne Medicines$3.81B7.06N/AN/A$34.10 per share7.20PLIProMetic Life SciencesC$39.91M0.00N/A3.94C$6.07 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABCNVIVO CannabisN/AN/A0.00∞N/AN/AN/AN/AN/AEMCEMCN/A$2.0514.28∞N/AN/AN/AN/AN/AONCBeOne Medicines-$644.79M-$3.72N/A345.76N/A-9.40%-7.55%-4.42%N/APLIProMetic Life SciencesN/A-C$63.06N/AN/AN/AN/AN/AN/AN/ALatest ONC, PLI, ABCN, and EMC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025ONCBeOne Medicines-$0.71$1.22+$1.93$0.01$1.12 billion$1.12 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABCNVIVO CannabisN/AN/AN/AN/AN/AEMCEMC$0.461.57%N/A22.44%N/AONCBeOne MedicinesN/AN/AN/AN/AN/APLIProMetic Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABCNVIVO CannabisN/AN/AN/AEMCEMCN/AN/AN/AONCBeOne Medicines0.051.961.71PLIProMetic Life Sciences37.474.063.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABCNVIVO CannabisN/AEMCEMC79.86%ONCBeOne Medicines48.55%PLIProMetic Life SciencesN/AInsider OwnershipCompanyInsider OwnershipABCNVIVO CannabisN/AEMCEMC0.40%ONCBeOne Medicines6.62%PLIProMetic Life SciencesN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABCNVIVO CannabisN/A194.41 millionN/ANot OptionableEMCEMCN/AN/AN/ANot OptionableONCBeOne Medicines11,000109.60 million102.34 millionN/APLIProMetic Life Sciences48723.31 millionN/ANot OptionableONC, PLI, ABCN, and EMC HeadlinesRecent News About These CompaniesNew PLI Treatise Helps Practitioners Navigate the Complexities of Trade Secret LawOctober 3, 2024 | ipwatchdog.comIRethinking rare diseases: treat the whole patientAugust 29, 2024 | pharmaphorum.comPPanetta Institute for Public PolicyMarch 31, 2024 | scu.eduS2024 Breakthrough Prizes in Life SciencesOctober 11, 2023 | the-scientist.comTTMC Life Sciences Bhd (TMCN)July 24, 2023 | investing.comLife Sciences Learning CommunityJune 13, 2023 | slu.eduSChicago Life Sciences SummitApril 21, 2023 | bisnow.comBCollege of Liberal Arts & SciencesApril 10, 2023 | alfred.eduALabviva nets $20M Series A to ease life science procurement processMarch 27, 2023 | endpts.comETrends that will shape the life sciences industry in 2023 and beyondFebruary 24, 2023 | hindustantimes.comHPharma sector gets first tranche of payment under under PLI schemeFebruary 24, 2023 | moneycontrol.comArithmos appoints Maurizio Giraudo as Managing Director of the new Life Sciences Business Consulting UnitFebruary 21, 2023 | finance.yahoo.comWEF, Telangana joins hands to start thematic centre on healthcare and life sciencesJanuary 18, 2023 | health.economictimes.indiatimes.comWorking on PLI schemes for more sectors: Piyush GoyalSeptember 24, 2022 | retail.economictimes.indiatimes.comTSX:CVE (CENOVUS ENERGY INC.)July 30, 2021 | fool.caNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesApplied Digital: Now the High-Stakes Race to Build BeginsBy Jeffrey Neal Johnson | June 17, 2025View Applied Digital: Now the High-Stakes Race to Build BeginsAddition by Subtraction: Intel’s New Strategy Energizes InvestorsBy Jeffrey Neal Johnson | June 27, 2025View Addition by Subtraction: Intel’s New Strategy Energizes Investors3 Notable Stocks Just Split: Which One Could Be the Big Winner?By Leo Miller | June 26, 2025View 3 Notable Stocks Just Split: Which One Could Be the Big Winner?Chime’s Smart IPO: Half the Valuation, Double the StrengthBy Jeffrey Neal Johnson | June 18, 2025View Chime’s Smart IPO: Half the Valuation, Double the StrengthRKLB Breakout Fails Near Highs: Should Investors Be Concerned?By Ryan Hasson | June 11, 2025View RKLB Breakout Fails Near Highs: Should Investors Be Concerned?ONC, PLI, ABCN, and EMC Company DescriptionsVIVO Cannabis CVE:ABCNC$1.32 +0.07 (+5.60%) As of 08/3/2018ABcann Global Corporation manufactures and distributes medical cannabis. The company is headquartered in Napanee, Canada.EMC NYSE:EMCEMC Corporation (EMC) develops, delivers and supports the information technology (IT) industry's range of information infrastructure and virtual infrastructure technologies, solutions and services. EMC manages the Company as part of a federation of businesses: EMC Information Infrastructure, VMware Virtual Infrastructure, Pivotal and Virtustream. EMC's Information Infrastructure business provides a foundation for organizations to store, manage, protect, analyze and secure information. EMC's VMware Virtual Infrastructure business is engaged in virtualization and cloud infrastructure solutions that enable businesses to help transform the way they build, deliver and consume IT resources in a manner that is based on their specific needs. EMC's Pivotal business unites strategic technology, people and programs from EMC and VMware and has a platform that consists of data, agile development practices and a cloud independent platform-as-a-service.BeOne Medicines NASDAQ:ONC$245.49 +1.17 (+0.48%) As of 07/3/2025 01:00 PM EasternBeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.ProMetic Life Sciences TSE:PLIPrometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
